Aberrant methylation of GCNT2 is tightly related to lymph node metastasis of primary CRC

Anticancer Res. 2015 Mar;35(3):1411-21.

Abstract

Background: Glycoprotein expression profile is dramatically altered in human cancers; however, specific glycogenes have not been fully identified.

Materials and methods: A comprehensive real-time polymerase chain reaction (PCR) system for glycogenes (CRPS-G) identified several outstanding glycogenes. GCNT2 was of particular interest after GCNT2 expression and epigenetics were rigorously investigated in primary colorectal cancer (CRC).

Results: The highlights of this work can be summarized as follows: (i) Expression of GCNT2 was remarkably suppressed. (ii) Silenced expression of GCNT2 was reactivated by combined demethylating agents. (iii) Promoter DNA methylation of GCNT2 was silenced in CRC cell lines and tissues. Hypomethylation of GCNT2 variant 2 is tightly associated with lymph node metastasis in primary CRC. (iv) GCNT2 methylation level in the normal tissues also showed a close association with that in the tumor tissues and reflected lymph node metastasis.

Conclusion: We identified aberrant expression of GCNT2, which can be explained by promoter DNA hypermethylation. Hypomethylation of the GCNT2 variant 2 reflected lymph node metastasis of CRC in the tumor and normal tissues.

Keywords: GCNT2; colorectal cancer; epigenetics; glycogene; lymph node metastasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / pathology
  • CpG Islands
  • DNA Methylation*
  • Humans
  • Lymphatic Metastasis
  • N-Acetylglucosaminyltransferases / genetics*
  • Promoter Regions, Genetic

Substances

  • N-acetylglucosaminyltransferase IGnT
  • N-Acetylglucosaminyltransferases